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Abstract: The numbers of reported cases of coccidioidomycosis in Arizona and California 
have  risen  dramatically  over  the  past  decade,  with  a  97.8%  and  91.1%  increase  in 
incidence rates from 2001 to 2006 in the two states, respectively. Of those cases with 
reported race/ethnicity information, Black/African Americans in Arizona and Hispanics 
and African/Americans in California experienced a disproportionately higher frequency of 
disease compared to other racial/ethnic groups. Lack of early diagnosis continues to be a 
problem, particularly in suspect community-acquired pneumonia, underscoring the need 
for  more  rapid  and  sensitive  tests.  Similarly,  the  inability  of  currently  available 
therapeutics to reduce the duration and morbidity of this disease underscores the need for 
improved therapeutics and a preventive vaccine. 
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1. Introduction 
Coccidioidomycosis (also known as ―Valley Fever‖), is a disease caused by Coccidioides immitis 
and  C.  posadasii,  two  nearly  identical  species  of  pathogenic  fungi  found  only  in  the  Western 
Hemisphere. Coccidioides spp. grow in the top 2–8 inches of soil in semi-arid parts of the southwest 
region of the United States, parts of northern Mexico, and Central and South America, and produces 
arthroconidia,  highly  infectious  propagules  that  can  be  disrupted  from  the  ground  and  inhaled,  
where they can produce acute pulmonary infection in humans and many mammals [1-3]. Sixty percent 
of  people  infected  with  the  fungus  will  remain  asymptomatic  or  present  with  mild  respiratory 
symptoms [4]. Approximately 40% of infections result in symptomatic disease, typically arising one to 
four weeks after exposure, which can resemble ordinary influenza, with fever, cough, fatigue, dyspnea, 
headache, myalgia and arthalgia. The disease is considered non-transmissible, although rare instances 
of transmission have occurred, including via organ transplantation [5] and inhalation of spores growing 
in  visecro-cutaneous  fistulae.  A  low  percentage  of  symptomatic  infections  progress,  resulting  in 
extrathoracic dissemination, with hematogenous spread to the central nervous system, skin, joints, 
major organs or bones and result in chronic (months to years) and even fatal disease [6,7]. Persons at 
increased  risk  of  disseminated  coccidioidomycosis  include  immunocompromised  persons, 
e.g., HIV/AIDS, diabetics, pregnant women [8,9] and persons of certain race/ethnicities, particularly 
Blacks and Filipinos [10,11].  
The purpose of this article is to present information on the current incidence of disease and selected 
demographic information on those afflicted in Arizona and California, the two states most impacted by 
coccidioidomycosis. In addition, this article presents information on the need for earlier diagnosis of 
disease and improved diagnostic tests, reviews current and future therapeutics for the treatment of this 
disease, and, lastly, the possibility of developing a preventive vaccine for coccidioidomycosis. 
2. The Public Health Impact of Coccidioidomycosis in Arizona 
Every year, an estimated 150,000 people in the United States become infected with Coccidioides 
spp., and approximately 50,000 develop symptoms [12]. In the United States, Arizona has the highest 
number of reported cases, accounting for 60% of all national cases [13].  
The Arizona Department of Health Services (ADHS) continues to monitor coccidioidomycosis in 
order to determine optimal ways to control this disease and minimize its burden on the people of 
Arizona. In this section, we describe the epidemiology of reported coccidioidomycosis in Arizona, 
validate the coccidioidomycosis surveillance system, investigate the diagnosis of coccidioidomycosis 
in  patients  with  community-acquired  pneumonia,  and  assess  the  effects  of  coccidioidomycosis  
in Arizona. 
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2.1. Epidemiology of Coccidioidomycosis 
Physicians in Arizona began reporting cases of coccidioidomycosis to the ADHS in the 1930s. 
Noticeable increases in reported coccidioidomycosis cases became apparent in the early 1990s. From 
1990 through 1995, the number of annually reported cases more than doubled from 255 (7/100,000 
population) to 623 (15/100,000 population) [14]. This increase led the ADHS to change its reporting 
rules to make coccidioidomycosis a laboratory-reportable disease in 1997. Since implementation of 
this mandatory requirement, reports of coccidioidomycosis have drastically increased in Arizona. In 
2006,  the  number  of  cases  peaked  at  5,535  (89/100,000  population)  and  decreased  to  4,815 
(75/100,000  population)  in  2007  and  to  4,768  (73/100,000  population)  in  2008.  The  increase  in 
incidence of coccidioidomycosis could be due to a number of factors, including soil disturbance due to 
construction  for  Arizona’s  rising  population  and  an  influx  of  susceptible  individuals  into  the 
population [15,16]. In June 2009, a major commercial laboratory changed its reporting practice by 
beginning  to  report  positive  coccidioidomycosis  enzyme  immunoassay  (EIA)  results  without 
confirmation by immunodiffusion assay in accordance with Arizona reporting rules, thereby further 
increasing  the  number  of  reported  coccidioidomycosis  cases.  In  2009,  Arizona  reported 
10,233 coccidioidomycosis cases (155/100,000 population) (see Figure 1).  
Figure 1. Rates of reported coccidioidomycosis cases in Arizona, 1990–2009. 
 
In 2006–2008, the median age of patients with coccidioidomycosis was 52 years (mean = 51). Since 
2006,  the  median  age  has  been  decreasing.  In  2006,  the  highest  rate  was  in  75–79  year  olds 
(225/100,000).  In  2007  and  2008,  the  highest  rates  were  in  70–74  year  olds  (180/100,000  and 
168/100,000 respectively). Interestingly, in 2009, the median age of people with coccidioidomycosis 
was 47 years (mean = 47), while the highest rate was in 65–69 year olds (298/100,000) (Figure 2).  
During 2006–2008, 54% of patients with coccidioidomycosis were male (84/100,000), and 46% 
were female (72/100,000). Of note, in 2009, the majority of cases were female (55%, 169/100,000) 
whereas only 45% (138/100,000) were male; a reversal of the earlier period.  
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Figure 2. Rates of reported coccidioidomycosis cases by age group in Arizona, 2001–2009.  
 
Based  on  race  and  ethnicity  data,  the  highest  rates  of  coccidioidomycosis  occurred  in  African 
Americans, with a rate of 49/100,000 from 2006–2008 and 67/100,000 in 2009. The rates in Asians or 
Pacific Islanders were 27/100,000 from 2006–2008 and 36/100,000 in 2009. In American Indian or 
Alaska  Natives,  the  rates  were  24/100,000  from  2006–2008  and  37/100,000  in  2009.  White  
non-Hispanics had a rate of 17/100,000 from 2006–2008, and 28/100,000 in 2009 while Hispanics had 
a rate of 14/100,000 from 2006–2008, and 21/100,000 in 2009. However, it is important to note that 
only about 30% of coccidioidomycosis cases reported to the ADHS contain information about race and 
only about 20% contain information about ethnicity, so these numbers may be unreliable.  
The  highest  rates  of  coccidioidomycosis  cases  continue  to  occur  in  Arizona’s  most  populated 
counties of Maricopa, Pima, and Pimal, which experience arid to semiarid climates with mild winters 
and hot summers. Maricopa had rates of 97/100,000 from 2006–2008 and 204/100,000 in 2009. Pima 
had rates of 87/100,000 from 2006–2008 and 130/100,000 in 2009. Pinal had rates of 83/100,000  
from 2006–2008 and 155/100,000 in 2009. These rates are markedly different than rates in counties  
at  higher  elevations,  such  as  Apache  and  Coconino  (both  counties  had  rates  of  seven  cases 
per 100,000 population  from  2006–2008;  and  14  and  18  cases  per  100,000  population  in  2009, 
respectively). Interestingly, Yuma County, an area with similar climate conditions to Maricopa, Pima 
and Pinal, had low rates of coccidioidomycosis (seven cases per 100,000 population from 2006–2008 
and six cases per 100,000 population in 2009). 
Arizona continues to have high numbers of coccidioidomycosis cases. Comparing 2009 to previous 
years’ data, the influx of positive EIA reports of coccidioidomycosis has coincided with a decrease in 
the median age of coccidioidomycosis cases as well as a shift in the majority of cases being female 
rather than male. Although EIA testing is the easiest and least expensive to perform, is widely used and 
provides a faster turnaround time, its sensitivity and specificity are not fully established [17,18]. The 
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ADHS is carrying out further investigations in understanding EIA sensitivity and specificity in order to 
improve surveillance of coccidioidomycosis in Arizona. 
2.2. Monitoring Laboratory Reporting of Coccidioidomycosis 
The Council of State and Territorial Epidemiologist (CSTE) and the Centers for Disease Control 
and  Prevention  (CDC)  require  laboratory  and  clinical  criteria  to  meet  the  case  definition  for 
coccidioidomycosis. The laboratory criteria consist of positive culture, histopathologic or molecular 
evidence; or immunologic evidence in the form of detection of IgM or IgG by immunodiffusion (ID), 
enzyme  immunoassay  (EIA),  latex  agglutination,  tube  precipitin  or  complement  fixation.  Clinical 
criteria require influenza-like signs and symptoms; pneumonia or other pulmonary lesion; erythema 
nodosum  or  erythema  multiforme  rash;  involvement  of  bones,  joints,  or  skin  by  dissemination; 
meningitis; or involvement of viscera and lymph nodes. Because of Arizona’s large number of cases 
and limited resources, ADHS utilizes only the laboratory component of the CSTE coccidioidomycosis 
case definition. 
In  2007,  two  major  laboratories  (Laboratory  A  and  Laboratory  B)  accounted  for  46%  of  all 
coccidioidomycosis cases reported to the state health department. In order to validate public health 
reporting  of  coccidioidomycosis,  data  on  positive  coccidioidomycosis  tests  were  obtained 
retrospectively from the two laboratories for the period of March through May 2008, independent of 
routine  reporting.  During  the  validation  period,  Laboratory  A  used  EIA  as  a  screening  tool  and 
routinely  only  reported  positive  coccidioidomycosis  results  that  were  confirmed  by  either 
immunodiffusion  or  complement  fixation.  Laboratory  B  reported  any  positive  results  from 
immunodiffusion, complement fixation or EIA testing. These positive tests underwent three rounds of 
validation:  the  results  were  first  compared  to  Arizona’s  surveillance  database,  which  tracks  only 
incidence reporting and not repeat or chronic testing, using an exact match on first and last name and 
birth  date;  this  database  contains  coccidioidomycosis  cases  reported  since  January  2006.  Second, 
unmatched results were compared to a historical database, which contains reports from 1998 through 
2005, using the same matching criteria of first and last name and date of birth. This step was conducted 
since coccidioidomycosis cases are only added to Arizona’s database once, regardless of the number of 
tests conducted; a 2008 test that matches a 2004 case was presumably not entered in 2008 because it 
was received in the earlier year. Finally, any remaining unmatched results were hand-matched to both 
databases to identify matches with possible misspellings or missing information.  
This validation showed that 651 (98%) of 664 patients with records provided to the state health 
department in the validation data matched for Laboratory A. Laboratory B matched for 427 (85%) of 
517 patients  with  positive  tests  reported.  Missing  reports  were  more  likely  to  be  EIA  tests  than 
complement  fixation  or  immunodiffusion.  These  findings  provide  validation  that  most 
coccidioidomycosis  tests  are  being  reported  to  the  state  health  department  from  these  two 
large laboratories.  
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2.3. Coccidioidomycosis as a Cause of Community-Acquired Pneumonia 
The  clinical  syndrome  of  coccidioidomycosis  is  very  similar  to  other  respiratory  diseases,  and 
difficult to recognize for both the providers and the public. A small study in Pima County established 
that 16 (29%) of 55 cases of community-acquired pneumonia (CAP) had positive serological tests for 
coccidioidomycosis, and that symptoms were insufficient to distinguish coccidioidomycosis from other 
pneumonias [19]. Another small study in Maricopa County found that 6 (17%) of 35 CAP patients 
with paired testing had coccidioidomycosis [20]. However, testing of CAP patients has been shown to 
be performed infrequently. A study at two healthcare systems in Maricopa County found that only 2% 
and 13% of ambulatory CAP patients were serologically tested for coccidioidomycosis [21]. In 2006, 
ADHS  made  a  strong  recommendation  to  test  patients  with  symptoms  of  CAP,  based  on  the 
knowledge  that  in  areas  where  Coccidioides  spp.  are  endemic  coccidioidomycosis  represents  a 
substantial underlying cause of CAP. 
In order to further evaluate this recommendation, ADHS conducted an investigation at two large 
sentinel  hospitals  in  Pima  County.  All  patients  with  a  diagnosis  of  pneumonia  admitted  to  the 
emergency departments from these two hospitals from 2007–2008 were screened to determine the 
proportion tested for coccidioidomycosis. Enhanced chart review was used to determine those that had 
community-acquired pneumonia. A stricter definition for community-acquired pneumonia was used 
for enrollment than in previous studies [19]. Patients were classified as having CAP if they had the 
International Classification of Diseases, 9th revision codes beginning with 480–487 (included all types 
of  pneumonia  and  influenza),  radiographic  evidence  of  a  new  infiltrate  documented,  at  least  one 
respiratory sign or symptom, and reported or observed fever or chills. The proportion of CAP patients 
receiving a test for coccidioidomycosis was below 10%, but rose to over 40% at the end of the first 
year. Targeted education to emergency room physicians at these hospitals may have increased the 
testing of patients. Physician educational efforts included presentations by an ADHS infectious disease 
physician and an educational poster prompting physicians to test CAP patients for coccidioidomycosis. 
In addition, in collaboration with the University of Arizona’s Valley Fever Center for Excellence 
(VFCE), ADHS developed a continuing medical education (CME) course, designed brochures and 
released a public service announcement encouraging patients to request that their doctors test them for 
coccidioidomycosis if they are experiencing cough, fever, and/or exhaustion. Furthermore, ADHS is 
currently conducting surveillance of severe acute respiratory infections and will be testing patients for 
coccidioidomycosis among other etiologies.  
The underdiagnosis and misdiagnosis of coccidioidomycosis represent a public health concern as 
patients with this disease often incur weeks to months of disability and time away from work. These 
illnesses also utilize significant amounts of medical resources, including hospitalizations, resulting in a 
tremendous economic burden (detailed more fully, below). As a result, there needs to be increased 
attention for seeking diagnosis earlier in patients with CAP and endemic exposure to Coccidioides spp., 
as recommended in current practice guidelines [22]. In addition to providing a patient with an exact 
diagnosis,  other  potential  benefits  would  be  decreasing  unneeded  and  ineffective  treatment  with 
antibacterial  drugs,  reducing  the  need  for  many  other  diagnostic  tests  and  procedures,  and  the 
possibility  of  identifying  earlier  the  infrequent  but  serious  complication  of  hematogenous  spread Int. J. Environ. Res. Public Health 2011, 8                 
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beyond the chest, resulting in disseminated sites of infection that are more difficult and expensive  
to treat. 
2.4. Enhanced Surveillance of Coccidioidomycosis 
In 2007, ADHS initiated enhanced surveillance of coccidioidomycosis to characterize the effects of 
this disease on Arizona’s population, healthcare system, and economy and to validate its use of the 
laboratory-exclusive coccidioidomycosis case definition. Every tenth patient with coccidioidomycosis 
that was reported to the state health department was interviewed using a standardized questionnaire. 
Interviewees  were  asked  questions  regarding  signs  and  symptoms  of  coccidioidomycosis,  
healthcare-seeking  behaviours  and  treatment,  whether  they  had  known  about  coccidioidomycosis 
before their diagnoses, and how the disease affected their daily lives. A total of 493 (9%) people were 
interviewed out of 5,664 coccidioidomycosis cases reported from January 2007 through February 2008. 
The results of the study have been reported previously [23]. 
This investigation found that persons with coccidioidomycosis waited a median of 11 days before 
they sought healthcare for their symptoms, and it took a median of 23 days from the day they sought 
healthcare to the day that coccidioidomycosis was diagnosed. Patients reported a median of two visits 
to  a  healthcare  provider  before  a  Coccidioides  test  was  ordered.  Over  one-fourth  (26%)  visited  a 
healthcare provider more than 10 times for their illness. Almost half (44%) of coccidioidomycosis 
patients  visited  an  emergency  department  during  the  course  of  their  illness.  Over  40%  were 
hospitalized overnight for their illness. Hospital charges totaled $86 million among Arizonans who had 
primary or secondary diagnoses of coccidioidomycosis in 2007 (median charge of $30,000 and mean 
charge of $49,000 per visit). 
Notably, persons with coccidioidomycosis experienced symptoms for a median of 120 days. Out of 
the 493 patients interviewed, 225 (46%) were employed at the time of illness. Out of those employed, 
167 (74%) missed a median of 14 days from work. Daily activities could not be performed for a 
median of 47 days for 369 (75%) patients. 
Persons with coccidioidomycosis who knew about the disease before seeking healthcare were more 
likely to get an earlier diagnosis of the disease than those who did not know about the disease (median 
20 days vs. 25 days, p = 0.04) and were also twice as likely to ask their healthcare providers to  
test  them  for  coccidioidomycosis  (95%  confidence  interval  (CI)  1.0–3.2,  p  =  0.05).  Furthermore, 
Caucasian patients of were more likely to know about coccidioidomycosis before their diagnoses than 
were patients of other racial groups (95% CI 1.7–4.3, p < 0.01). 
Antifungal  treatment  for  coccidioidomycosis  was  prescribed  for  303  (61%)  of  patients.  About  
60% (289) were treated with antibacterial agents. Of those, 92 (32%) received more than one course of 
antibacterial drugs. Of the 493 patients, 469 (95%) met the CSTE clinical case definition. Thirteen (3%) 
reported no symptoms.  
The enhanced surveillance investigation revealed substantial personal and economic burdens due to 
coccidioidomycosis among Arizonans with respect to delays in diagnosis, duration and severity of 
illness,  and  healthcare  utilization  and  costs.  This  investigation  also  highlighted  the  importance  of 
public and provider education in reducing delays in diagnosis and thereby minimizing unnecessary use 
of antimicrobial drugs, relieving patient anxiety, and enabling early recognition and treatment of this Int. J. Environ. Res. Public Health 2011, 8                 
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disease.  These  findings  also  support  the  use  of  a  laboratory-exclusive  case  definition  in 
coccidioidomycosis-endemic  areas  for  surveillance  purposes  to  reduce  resources  needed  for  an 
accurate assessment of the extent of the disease and its effects. 
2.5. Conclusions 
In  summary,  Arizona  surveillance  data  demonstrate  a  high  burden  of  disease  due  to 
coccidioidomycosis in the state, and the surveillance system accurately reflects coccidioidomycosis 
reports  from  laboratories.  With  the  recent  changes  in  coccidioidomycosis  reporting  by  a  major 
laboratory and perhaps other laboratories and hospital facilities, further analysis should be done to 
characterize this disease. Educational efforts in testing patients with CAP have increased awareness 
and  diagnosis  of  coccidioidomycosis.  Enhanced  surveillance  highlights  the  significant  symptom 
duration and delays in diagnosis of this disease and also further supports the need for physician and 
provider education in reducing these delays for optimal patient care and treatment. Because of the huge 
effects  of  this  disease  upon  Arizona’s  residents,  healthcare  system  and  economy,  continued 
surveillance, research, and education of this disease is necessary. 
3. The Public Health Impact of Coccidioidomycosis in California, 2001–2009 
To  describe  the  epidemiology  of  coccidioidomycosis  in  California  during  2001–2009,  cases  of 
coccidioidomycosis reported to the California Department of Public Health (CDPH) between 2001 and 
2009 and cases of hospitalized coccidioidomycosis included in the California Patient Discharge Data 
Set 2001–2008 were reviewed. 
3.1. Materials and Methods 
The  California  Department  of  Public  Health  (CDPH)  utilizes  a  passive  reporting  surveillance 
system for coccidioidomycosis cases and outbreaks. Health care providers and, most recently, since 
2010  laboratories  are  mandated  by  the  California  Code  of  Regulations,  Title  17,  to  report  cases  
of coccidioidomycosis to their local health departments (LHDs) that, in turn, report these cases to 
CDPH [24]. The case definition for surveillance reporting is based on clinical criteria and laboratory 
evidence of infection defined by the Council of State and Territorial Epidemiologists (CSTE) and the 
federal Centers for Disease Control and Prevention (CDC) [25].  
We analyzed the CDPH surveillance data on coccidioidomycosis cases with an estimated date of 
illness onset from 2001 through 2009. The estimated onset date for each case was defined as the date 
closest to the time when symptoms first appeared, ranging from the first appearance of symptoms to 
the date the report was made to CDPH. A probabilistic de-duplication algorithm was used to include 
only the first report of the disease per person during the study period. Additionally, the provisional 
reported data (as of second week of January 2011) of cases with estimated illness onset date of 2010 
were  de-duplicated  and  reviewed.  Publications  of  outbreaks  or  locally  increased  cases  in  special 
populations during the study period were briefly discussed.  
The coccidioidomycosis hospitalization data for the period 2001–2008 were extracted from the 
California Patient Discharge Data Set. The data set included inpatient discharge diagnosis from all Int. J. Environ. Res. Public Health 2011, 8                 
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California  nonfederal  hospitals.  The  data  were  probabilistically  de-duplicated  to  include  first 
hospitalized cases during the study period. Cases with codes for coccidioidomycosis (114.0–114.5  
and 114.9) from the International Classification of Diseases, Ninth Edition, were selected.  
We calculated state and county-specific case rates by the estimated onset year as well as the yearly 
hospitalization rates per 100,000 California population. To calculate rates, we used projections for 
state and county specific population totals that were published by the State of California, Department 
of Finance [26]. Rates were defined as unreliable if their coefficient of variations (relative standard 
errors)  were  23  percent  or  more  (a  threshold  recommended  by  the  National  Center  for  Health 
Statistics). Analyses were conducted using SAS Release 9.1 (SAS Institute, Inc, Cary North Carolina). 
We  examined  temporal  trends  by  plotting  incidence  cases  (de-duplicated  to  account  for  previous 
reports on a given subject) and rates, first hospitalization cases and rates, and percent hospitalization 
over time. Spatial trends of cases were depicted by mapping county-specific average incidence rates 
for  years  2001–2004,  2005–2008,  and  2009  using  ArcGIS  version  9.3  (ESRI,  Inc,  Redlands, 
California). Unreliability of rates was marked on the maps using dash lines.  
3.2. Results 
As of June 2010, CDPH received reports of 20,931 cases of coccidioidomycosis with estimated 
illness onset dates from 2001 through 2009, reaching a peak at 3,043 reported cases in 2006 (Figure 3). 
The annual incidence rate per 100,000 population increased by 91.1% from 4/100,000 in 2001 to 
8/100,000 in 2006, and decreased by 33.4% subsequently to approximately 5/100,000 in 2009. 
Figure 3. Coccidioidomycosis incidence cases and incidence rates in California, 2001–2009. 
 
The  majority  of  the  20,931  reported  cases  were  male  (65%).  There  were  increasing  trends  in 
incidence rates in age groups 0–4 to 25–29 across all years (Figure 4). The incidence rates stayed 
relatively steady in age groups 25–29 to 50–54, and declined with some fluctuations in age groups  
55–59 and older. The incidence rate was highest among those 30–34 years old in the peak year 2006 
(13 per 100,000).  
   Int. J. Environ. Res. Public Health 2011, 8                 
 
 
1159 
Figure 4. Coccidioidomycosis incidence rates by age-group in California, 2001–2009. 
 
Cases with complete race/ethnicity data reported Hispanic and Black, non-Hispanic races/ethnicities 
more  frequently  than  would  be  expected  based  on  the  overall  demographic  profile  of  California 
(Figure 5), as well as the most highly-endemic areas of California (Fresno, Kern, Kings, Madera, San 
Luis Obispo, and Tulare) (Figure 6). Thirty-five percent of the records in California and fifty percent 
of the records in the California Coccidioides-endemic areas were missing race/ethnicity information; 
therefore, incidence rates were not calculated.  
Figure 5. Coccidioidomycosis incidence cases and population by reported race/ethnicity in 
California, 2001–2009. 
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Figure 6. Coccidioidomycosis incidence cases and population by reported race/ethnicity in 
California Coccidioides-endemic areas (Fresno, Kern, Kings, Madera, San Luis Obispo, 
and Tulare), 2001–2009. 
 
There were 9,898 unique hospitalized cases from 2001 through 2008. The highest number of cases 
and hospitalization rates were in 2006 (1,626 cases; 4 per 100,000) (Figure 7).  
Figure 7. Coccidioidomycosis first hospitalization cases and rates in California, 2001–2008. 
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Figure  8.  Coccidioidomycosis  incidence  and  first  hospitalization  rates  and  percent 
hospitalization in California, 2001–2008. 
 
The counties of Kern (annual average rate: 144/100,000; cumulative cases: 9,998), Kings (annual 
average rate: 68/100,000; cumulative cases: 900), Tulare (annual average rate: 37/100,000; cumulative 
cases:  1,374),  Fresno  (annual  average  rate:  33/100,000;  cumulative  cases:  2,635),  Madera  (annual 
average  rate:  15/100,000;  cumulative  cases:  196),  and  San  Luis  Obispo  (annual  average  rate: 
31/100,000; cumulative cases: 734) had the highest annual average incidence rates during the study 
period. These counties are established as being Coccidioides-endemic areas and their cumulative cases 
represent 76% of all cases reported during the study period. There were only five out of the 58 counties 
in California with no reported cases during the entire study period. Figure 9 presents county-specific 
cumulative incidence ranges per 100,000 population for years 2001–2009 across California. Counties 
with unreliable rates within the time period were marked with hatched lines. 
The study sought to include the most recently reported data by examining the 2010 provisional  
data, particularly since coccidioidomycosis became laboratory-reportable in California in 2010. As  
of  the  second  week  of  January  2011,  3,461  (9  per  100,000  population)  provisional  cases  of 
coccidioidomycosis with estimated illness onset dates in 2010 have been reported to CDPH.  
Regarding focal outbreaks or clusters of infections, during the study period, there were two reported 
outbreaks in California, one in 2001 among United States Navy SEALS training in an endemic area, 
and one in 2007 among civilian construction workers excavating soil at a military base. In the Navy 
SEALs outbreak, ten (45%) of 22 men had serologic evidence of recent Coccidioides infection and 
five (50%) of the ten had abnormal chest radiographs [27]. In the construction workers outbreak, eight 
(67%) of 12 men had serological evidence of infection and seven had abnormal chest radiographs [28]. 
During  2002–2006,  a  naval  air station  in  the California  Central  Valley  reported  increased  rate  of 
coccidioidomycosis among active duty personnel with increased disseminated cases to a high of 30% 
of diagnosed cases by 2006 [29]. And substantially increased numbers of cases have been reported 
among inmates of California State prisons situated in the endemic area [30,31]. Int. J. Environ. Res. Public Health 2011, 8                 
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Figure 9. Coccidioidomycosis county-specific incidence rate ranges, California, 2001–2009. 
 
3.3. Discussion, Limitations, and Comments 
During 2001–2009, the annual number of incidence cases and rates of reported coccidioidomycosis 
in California increased steadily to a peak in 2006, and then decreased. The annual number of incidence 
cases and rates during this period were higher than the annual numbers and rates between 1995 and 
2000  (data  not  shown).  The  annual  number  and  rate  of  coccidioidomycosis  hospitalizations  have 
followed the trend of reported cases during this time, peaking in 2006 and then decreasing.  
The distribution of reported cases by counties in California reflected the importance of the endemic 
San Joaquin Valley and San Luis Obispo in the Central Coast, but cases have been reported from all 
except five counties during this time. Inmates of California State prisons situated in the endemic areas 
contributed to the incidence of coccidioidomycosis in the Coccidioides-endemic areas. Further studies 
are needed to describe the demographic and risk factors of inmate vs. non-inmate cases in California. 
The increase in the number of provisional 2010 incidence data compared to 2009 could partly be due 
to the impact of making the disease laboratory-reportable in California. However, the 2010 data are 
provisional at this point and may still be subject to reporting delays. Future studies are needed to assess 
any  possible  impact  of  the  2010  change  in  regulation  on  timeliness  and  completeness  of  the 
surveillance data. Collectively, the data support the conclusion that coccidioidomycosis continues to be 
an important public health problem and burden in California 
4. Diagnosis and Treatment of Coccidioidomycosis 
The  spectrum  of  coccidioidomycosis  was  very  well  appreciated  long  before  the  first  effective 
antifungal  drug,  amphotericin  B,  was  available  as  a  treatment.  For  example,  a  monograph  on 
coccidioidomycosis, which is quite true to our current understanding of disease manifestation, was 
published in 1958 [32], just about the time amphotericin B was first coming into use [33]. It is quite Int. J. Environ. Res. Public Health 2011, 8                 
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clear  that  most  patients  who  become  ill  exhibit  findings  of  a  respiratory  tract  infection  and  that, 
whether treated or not, most infections resolve. When amphotericin B was the only treatment available, 
its toxicity, untoward reactions, and its parenteral route of administration resulted in recommendations 
for its use only in patients with clear indication of progressive, coccidioidal infections and not in 
patients with the self-limited form of disease, commonly known as Valley Fever.  
Because  most  coccidioidal  infections  are  self-limited,  many  clinicians  discount  the  value  of 
diagnosing the initial coccidioidal pneumonia, even within areas highly endemic for coccidioidomycosis, 
and do not routinely test patients with community-acquired pneumonia (CAP) for coccidioidomycosis 
even  though  the  likelihood  of  this  cause  approaches  30%  [19,20].  As  mentioned  above,  a  study  
of  approximately  150  outpatients  in  Phoenix,  Arizona,  found  that  only  2%  to  13%  of  patients  
with  community  acquired  pneumonia  in  a  one-year  period  were  tested  serologically  for 
coccidioidomycosis  [21].  However,  what  has  re-emerged  in  the  recent  surveillance  activities  in 
Arizona [23], is that even for patients with the self-limited pulmonary syndrome the impact of this 
disease is often substantial. As detailed elsewhere in this review, patients with coccidioidomycosis 
often  incur  weeks  to  months  of  disability  and  time  away  from  work.  These  illnesses  also  utilize 
significant amounts of medical resources, including hospitalization. These findings are consistent with 
the descriptions published seventy years earlier [34,35] that are likely not familiar to most clinicians. 
As a result, there needs to be increased attention for seeking diagnosis earlier in patients with CAP and 
possible  endemic  exposure  to  Coccidioides  spp.,  as  is  the  recommendation  of  current  practice 
guidelines [22]. In addition to providing a patient with an exact diagnosis, in itself very valuable, other 
potential  benefits  would  be  reducing  unneeded  and  ineffective  treatment  with  antibacterial  drugs, 
reducing the need for many other diagnostic tests and procedures, and the possibility of identifying 
earlier the infrequent but serious complication of hematogenous spread beyond the chest, resulting in 
disseminated sites of infection that are more difficult and expensive to treat.  
4.1. Improving Diagnostics for Early Coccidioidal Infections. 
The increased interest in earlier diagnosis of coccidioidal infections has brought into focus the 
limitations of current diagnostic tests for coccidioidomycosis. Although isolating Coccidioides spp. in 
culture  results  in  a  definitive  diagnosis,  fungal  cultures,  especially  in  the  outpatient  setting,  are 
infrequently  obtained  in  patients  with  CAP.  Culture  is  more  sensitive  than  direct  examination  of 
bronchoscopic specimens [36], and presumably would be very sensitive in the diagnosis of active 
coccidioidal pneumonia. However, the sensitivity of sputum cultures is not certain and the ability to 
obtain sputum from patients with coccidioidal pneumonia is often challenging since their coughing is 
frequently described as ―non-productive.‖ Even when fungal cultures of sputum are submitted, there is 
frequently  a  delay  of  one  or  more  weeks  before  a  positive  result  is  returned.  Skin  tests  with 
coccidioidin or spherulin were widely used as a diagnostic for many decades, until being withdrawn 
from the market in the 1980’s (although a commercial entity is currently seeking FDA approval to  
re-launch spherulin in the USA). As a result of these limitations, a large majority of patients with 
suspected coccidioidal CAP are tested serologically, instead. Conventional immunodiffusion tests for 
anti-coccidioidal antibodies were derived from extensive experience spanning several decades [37] and 
provides strong evidence that positive tests are often indicative of recent or active infection. However, Int. J. Environ. Res. Public Health 2011, 8                 
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their sensitivity for detecting diagnostic antibodies in the first few weeks of illness is not nearly as 
great as later in infection or in patients with chronic disease. In one report, conventional test results 
were non-diagnostic in first serum specimens from one-third to two-thirds of patients studied [18]. 
Increasing the sensitivity of diagnostic tests for early coccidioidal infection could potentially be 
accomplished by any of several approaches. One would be to improve serologic testing itself. For 
example,  a  commercially  available  enzyme-linked  immunoassay  kit,  Premier  EIA,  (Meridian 
Diagnostics,  Inc.,  Cincinnati,  OH)  may  be  more  sensitive  than  the  conventional  immunodiffusion  
tests [38]. However, the documentation for its performance is scant and the proprietary antigen that the 
test uses to detect anti-coccidioidal antibodies has not been publically disclosed. 
Another  approach  would  be  to  use  nucleic-acid  amplification  technologies  to  detect  
Coccidioides-specific  sequences  in  clinical  specimens.  In  an  early  report,  a  PCR-based  assay 
demonstrated that such sequences were present in patients [39], and more recent reports have shown 
good correlation between a real-time PCR method and culture results from bronchoalveolar lavage 
fluids [40] and the ability to detect coccidioidal DNA before the appearance of diagnostic antibodies in 
patients [41]. At least one medical center has systematically employed an experimental PCR method in 
suspected cases, targeting the ITS2 region of the fungal genome, and has reported results compared to 
traditional culture methods [42]. While showing promise as a more rapid test, it is not clear that the 
method can supplant more traditional diagnostic methods. 
Detecting  coccidioidal  antigens  in  clinical  specimens  might  also  improve  early  detection  of 
coccidioidomycosis. Several research reports have suggested that circulating coccidioidal antigens are 
present during naturally-acquired human infections [43-45]. In one report, antigenemia appeared to 
precede the detection of antibodies [18], and others have demonstrated polysaccharide antigenuria and 
antigenemia in patients with very extensive coccidioidal infections [46,47].  
4.2. Current and Future Therapies for Coccidioidomycosis 
Amphotericin B was once the only effective treatment for coccidioidomycosis [48], and is still 
considered an effective, perhaps the most effective antifungal agent [49]. In vitro, amphotericin B 
exerts its inhibitory effort almost immediately and some clinicians believe that clinical response is 
fastest with this drug as compared to newer agents. A major drawback to using amphotericin B is that 
it  requires  parenteral  administration,  which  makes  long-term  treatment  more  cumbersome.  As  a 
therapy for coccidioidal meningitis, intravenous therapy with the original formulation of amphotericin 
B  was  not  effective.  While  experimental  evidence  raises  the  possibility  that  some  of  the  lipid 
formulations administered intravenously may be better [50,51], this has not yet been corroborated with 
clinical  experience.  As  a  result,  when  amphotericin  B  is  used  to  treat  coccidioidal  meningitis,  it 
requires administration directly into the CSF [52,53], which adds additional risk and morbidity to its 
use. Another major difficulty with amphotericin B therapy is that it is very toxic; fever, nausea, and 
myalgia  are  frequent  in  association  with  administration.  Dose-related  toxicity  commonly  involves 
major  organs  and  cumulative  toxicity  may  result  in  permanent  renal  failure,  requiring  dialysis  or  
organ transplantation. 
Fortunately, over the past three decades, therapy for coccidioidal infections has improved [54]. 
Miconazole  was  the  first  alternative  found  to  be  effective  against  coccidioidal  infections, Int. J. Environ. Res. Public Health 2011, 8                 
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demonstrating  the  potential  for  the  azole  class  of  antifungals  [55].  Subsequently,  orally-effective 
congeners, first ketoconazole [56,57] and later fluconazole and itraconazole [58], have largely replaced 
amphotericin  B  as  first-line  treatment.  Although  fluconazole  and  itraconazole  are  similar  in  their 
effectiveness, itraconazole may be more effective for skeletal lesions. Their relative safety and ease of 
administration has allowed treatment regimens to be extended for years and, in some patients, for  
life-long  courses  of  treatment.  Azole  therapy  has  been  particularly  dramatic  for  the  treatment  of 
coccidioidal meningitis, which previously required intrathecal amphotericin B administration [59-61]. 
The newer azoles voriconazole and posaconazole have been approved by the FDA as treatment for 
some systemic mycoses and the relatively small amount of information available about their use in 
treating coccidioidomycosis suggests they may also be useful in treating this disease [62-66].  
With these advances, there remain several limitations of current treatments. A notable gap in our 
understanding in managing coccidioidal infections is the complete absence of randomized trials of any 
azole antifungal therapy as a treatment of early coccidioidal infections. A prospective observational 
study at one Veterans Administration medical center compared the outcome of patients with early 
coccidioidal pneumonia who were or were not treated with an oral azole (usually fluconazole) [67]. 
There was no evident difference between the two groups in their rates of improvement. Moreover, 
complications of infection only occurred in the group of patients treated with antifungals after their 
treatment was discontinued. In other studies where subjects were treated because of chronic pulmonary 
or extrapulmonary infections, azole treatment did not always result in measurable improvement, with 
treatment  failure  occurring  in  approximately  20%  to  40%  of  cases  [58,62].  Of  patients  who  did 
improve during treatment, many relapsed even after protracted courses of treatment were completed. 
These findings have led to the recommendation that for patients with the most serious manifestations 
of coccidioidomycosis, including all patients with coccidioidal meningitis [41], treatment be continued 
indefinitely. Collectively, these results underscore the need for new classes of therapeutics that can 
result in cures rather than just amelioration of disease. 
Nikkomycin Z, a new antifungal drug which targets the cell wall of chitin-rich fungi, is currently in 
development  for  treating  coccidioidomycosis.  Nikkomycin  Z,  originally  discovered  in  the  1970s, 
showed striking therapeutic effects when administered orally to mice infected with Coccidioides spp. 
[68]. Development of nikkomycin Z as a treatment for systemic mycoses was begun in the 1990’s but 
the sponsoring company went out of business and, without a commercial sponsor, the development 
program stalled. In 2005, the inactive IND for nikkomycin Z was transferred to the University of 
Arizona, which activated the program and completed a phase I multidose study [69]. A company, 
Valley Fever Solutions, has been formed primarily to assist the University of Arizona in developing 
the drug’s development [70]. Current efforts are focused upon manufacturing more nikkomycin Z 
which will be used in phase II clinical trials. It is hoped that with continued development, clinical 
confirmation of the preclinical data will drive the commercialization of this compound, offering an 
attractive therapeutic option in the treatment of coccidioidomycosis. 
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5. A Preventive Vaccine for Coccidioidomycosis 
Based on epidemiologic and preclinical animal studies that date back to the 1940’s and 50’s, it had 
been established that persons who recovered from coccidioidal infection had durable immunity to  
re-infection that was, in the absence of profound immune suppression, life-long [71]. A large body of 
clinical  and  preclinical  data  that  followed  solidified  this  finding,  supporting  the  possibility  that  a 
preventive vaccine could be created, which, if utilized, could impact the incidence and/or the severity 
of disease and the associated public health burden and economic consequences [72-74]. 
Trials in humans utilizing formalin-killed vaccine preparations of both the mycelial and spherule 
phases of the dimorphic fungus have been conducted, but uniformly resulted in local and systemic 
reactogenicity  that  limited  the  amount  of  the  experimental  vaccines  that  could  be  administered,  
with  the  net  effect  that  the  doses  proved  insufficient  to  trigger  a  uniformly  sufficient  immune  
response [75,76]. 
Because of the unacceptable toxicity of the killed whole-cell vaccine preparations, more recent 
efforts to create an effective vaccine have primarily focused on use of recombinant or native soluble 
protein formulations or live attenuated vaccines [77-84]. However, the challenges in discovering and 
developing an effective, preventive vaccine for coccidioidomycosis are daunting. The understanding of 
innate immunity and the basis for eliciting a protective immune response to coccidioidal infection 
continues to evolve. Many of the foundational immune components critical to protection are known; 
infection triggers a Class II-restricted T helper 1 (Th1) cellular immune response that is mediated, in 
part, by macrophages activated by IFN-γ and IL-12, which have been shown to be crucial in locally 
controlling infection [7,85-87]. Newer data also suggest a role for IL-17 [88]. Additionally, while 
earlier dogma held that antibodies were not a part of a protective immune response (with titers of IgG 
to coccidioidal antigens actually proportional to the severity of disease), more current studies have 
ascribed a role for humoral immunity, particularly in the early phases of disease [89]. 
Transient duration of protection induced by protein-based coccidioidal vaccines has been an issue, 
with some experimental vaccines that initially provide protection against lethal challenge later failed to 
prevent  recurrence  of  progressive,  fatal  disease  in  mice  [90,91].  In  addition,  adjuvants  that  are 
appropriate to help elicit a robust Th1 response have not yet met a safety profile in humans that is 
suitable for widespread use in a vaccine for what is largely a benign disease. 
The cost-effectiveness of a coccidioidal vaccine was projected in one study. Vaccination amongst 
various age groups in the endemic area was predicted to be cost saving among infants, teens, and 
resident and immigrant adults, but was economically unfavorable among resident seniors and among 
immigrant seniors. [92]. As one metric, based on the assumptions and models detailed in that study, 
vaccination for coccidioidomycosis in the endemic area was predicted to save 0.03 to 0.4 life days per 
person vaccinated over no vaccination among various populations. In comparison, infant vaccination 
against measles, mumps, rubella, and pertussis each save 2.7, 3, 0.3 and 3.3 life days, respectively [93]. 
However,  an  assessment  of  the  cost-effectiveness  of  a  coccidioidal  vaccine  should  also  take  into 
account the prolonged morbidity, the number of work days and quality of life lost, and the familial and 
societal burdens of this disease; criteria that have particular importance given the increasing incidence 
of this disease, with millions of people living in or moving to the endemic areas. Int. J. Environ. Res. Public Health 2011, 8                 
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6. Discussion 
We found that the incidence of coccidioidomycosis has dramatically increased over the past decade, 
and that the case and total economic costs associated with acquisition of symptomatic disease have 
substantially  increased  since  the  vaccine  cost-effectiveness  report  was  published  in  2001.  Despite 
enhanced  reporting  requirements  instituted  by  both  Arizona  and  California,  greater  physician  and 
provider education leading to more stringent surveillance and timely use of diagnostics is needed to 
reduce delays in diagnosis and the provision of optimal patient care and treatment. Because of the 
economic costs attributable to this disease, the burden on the private, public, and prison healthcare 
infrastructure,  the  toll  of  morbidity  on  the  afflicted  and  their  families,  and  the  lack  of  curative 
therapeutics, the need for improved therapeutics and a preventive vaccine for coccidioidomycosis have 
never been greater. 
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